Institutional shares held 83.9 Million
2.06M calls
1.52M puts
Total value of holdings $9.8B
$241M calls
$178M puts
Market Cap $10.2B
87,567,904 Shares Out.
Institutional ownership 95.81%
# of Institutions 528


Latest Institutional Activity in SRPT

Top Purchases

Q4 2024
Nordea Investment Management Ab Shares Held: 67.5K ($7.84M)
Q4 2024
Smith, Salley & Associates Shares Held: 7.31K ($848K)
Q4 2024
Everence Capital Management Inc Shares Held: 2.83K ($329K)
Q4 2024
Park Avenue Securities LLC Shares Held: 1.68K ($195K)
Q4 2024
Kbc Group Nv Shares Held: 3.7K ($430K)

Top Sells

Q4 2024
Assenagon Asset Management S.A. Shares Held: 132K ($15.4M)
Q4 2024
Sg Americas Securities, LLC Shares Held: 926 ($107K)
Q4 2024
Perfromance Wealth Partners, LLC Shares Held: 1.73K ($200K)
Q4 2024
Pacer Advisors, Inc. Shares Held: 20.1K ($2.33M)
Q4 2024
Linden Thomas Advisory Services, LLC Shares Held: 11.2K ($1.3M)

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at SRPT

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
174K Shares
From 21 Insiders
Grant, award, or other acquisition 41.8K shares
Exercise of conversion of derivative security 95.3K shares
Open market or private purchase 37K shares
Sell / Disposition
126K Shares
From 14 Insiders
Open market or private sale 96.6K shares
Bona fide gift 996 shares
Payment of exercise price or tax liability 28.8K shares

Track Institutional and Insider Activities on SRPT

Follow Sarepta Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SRPT shares.

Notify only if

Insider Trading

Get notified when an Sarepta Therapeutics, Inc. insider buys or sells SRPT shares.

Notify only if

News

Receive news related to Sarepta Therapeutics, Inc.

Track Activities on SRPT